KR20070104409A - 글루카곤 수용체 길항제로서의 치환된 티오펜 유도체, 제법및 치료 용도 - Google Patents

글루카곤 수용체 길항제로서의 치환된 티오펜 유도체, 제법및 치료 용도 Download PDF

Info

Publication number
KR20070104409A
KR20070104409A KR1020077018437A KR20077018437A KR20070104409A KR 20070104409 A KR20070104409 A KR 20070104409A KR 1020077018437 A KR1020077018437 A KR 1020077018437A KR 20077018437 A KR20077018437 A KR 20077018437A KR 20070104409 A KR20070104409 A KR 20070104409A
Authority
KR
South Korea
Prior art keywords
thiophene
biphenyl
amino
carbonyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077018437A
Other languages
English (en)
Korean (ko)
Inventor
마크 도널드 샤펠
스콧 유진 코너
앨리 에드워드 트립
궈신 주
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20070104409(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20070104409A publication Critical patent/KR20070104409A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077018437A 2005-02-11 2006-02-09 글루카곤 수용체 길항제로서의 치환된 티오펜 유도체, 제법및 치료 용도 Ceased KR20070104409A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65249205P 2005-02-11 2005-02-11
US60/652,492 2005-02-11

Publications (1)

Publication Number Publication Date
KR20070104409A true KR20070104409A (ko) 2007-10-25

Family

ID=36694345

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077018437A Ceased KR20070104409A (ko) 2005-02-11 2006-02-09 글루카곤 수용체 길항제로서의 치환된 티오펜 유도체, 제법및 치료 용도

Country Status (25)

Country Link
US (1) US8084489B2 (enExample)
EP (1) EP1856090B1 (enExample)
JP (1) JP4988604B2 (enExample)
KR (1) KR20070104409A (enExample)
CN (1) CN101115735B (enExample)
AT (1) ATE445609T1 (enExample)
AU (1) AU2006213894B2 (enExample)
BR (1) BRPI0607015A2 (enExample)
CA (1) CA2597073C (enExample)
CR (1) CR9304A (enExample)
CY (1) CY1109624T1 (enExample)
DE (1) DE602006009773D1 (enExample)
DK (1) DK1856090T3 (enExample)
EA (1) EA200701705A1 (enExample)
ES (1) ES2332470T3 (enExample)
IL (1) IL184932A0 (enExample)
MA (1) MA29432B1 (enExample)
MX (1) MX2007009661A (enExample)
NO (1) NO20074567L (enExample)
PL (1) PL1856090T3 (enExample)
PT (1) PT1856090E (enExample)
SI (1) SI1856090T1 (enExample)
TN (1) TNSN07313A1 (enExample)
WO (1) WO2006086488A2 (enExample)
ZA (1) ZA200706354B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1758853T1 (sl) * 2004-06-14 2010-05-31 Lilly Co Eli Antagonisti glukagonskega receptorja priprava inuporaba v terapiji
ES2494294T3 (es) 2007-02-09 2014-09-15 Metabasis Therapeutics, Inc. Antagonistas del receptor de glucagón
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2714207T3 (es) 2008-08-13 2019-05-27 Metabasis Therapeutics Inc Antagonistas de glucagón
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
BR112013016033A2 (pt) 2010-12-23 2018-06-05 Pfizer moduladores do receptor de glucagon
ES2597972T3 (es) 2011-02-08 2017-01-24 Pfizer Inc Modulador del receptor de glucagón
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
WO2015066252A1 (en) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
EP3350200A4 (en) 2015-09-18 2019-03-27 Wake Forest University Health Services ANGIOTENSIN (1 7) ANALOGUE AND ASSOCIATED PROCEDURES
EP3821917A1 (en) 2015-10-05 2021-05-19 Hettwer Holding ApS Compositions and methods for treatment of bone defects
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
SG11201901355SA (en) 2016-08-30 2019-03-28 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US12139546B2 (en) 2017-08-22 2024-11-12 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
TW202003453A (zh) 2018-02-13 2020-01-16 美商利根德製藥公司 升糖素受體拮抗劑
CN118496197A (zh) 2019-12-20 2024-08-16 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365622A1 (en) * 2001-12-03 2003-06-17 Novo Nordisk A/S Novel glucagon antagonists
AU2003233780A1 (en) * 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
WO2005118542A1 (en) * 2004-05-28 2005-12-15 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
SI1758853T1 (sl) * 2004-06-14 2010-05-31 Lilly Co Eli Antagonisti glukagonskega receptorja priprava inuporaba v terapiji

Also Published As

Publication number Publication date
WO2006086488A3 (en) 2006-12-14
EP1856090B1 (en) 2009-10-14
DK1856090T3 (da) 2009-11-30
JP2008530102A (ja) 2008-08-07
MA29432B1 (fr) 2008-05-02
EA200701705A1 (ru) 2008-02-28
NO20074567L (no) 2007-11-08
BRPI0607015A2 (pt) 2009-12-01
CN101115735B (zh) 2013-01-09
ATE445609T1 (de) 2009-10-15
MX2007009661A (es) 2007-09-25
WO2006086488A2 (en) 2006-08-17
IL184932A0 (en) 2007-12-03
PL1856090T3 (pl) 2010-02-26
CR9304A (es) 2008-03-31
TNSN07313A1 (en) 2008-12-31
CY1109624T1 (el) 2014-08-13
CA2597073A1 (en) 2006-08-17
ZA200706354B (en) 2008-11-26
JP4988604B2 (ja) 2012-08-01
US20100137417A1 (en) 2010-06-03
CA2597073C (en) 2014-11-25
SI1856090T1 (sl) 2010-02-26
PT1856090E (pt) 2009-11-18
CN101115735A (zh) 2008-01-30
EP1856090A2 (en) 2007-11-21
US8084489B2 (en) 2011-12-27
AU2006213894A1 (en) 2006-08-17
ES2332470T3 (es) 2010-02-05
DE602006009773D1 (de) 2009-11-26
AU2006213894B2 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
KR20070104409A (ko) 글루카곤 수용체 길항제로서의 치환된 티오펜 유도체, 제법및 치료 용도
KR100835496B1 (ko) 글루카곤 수용체 길항제, 제법 및 치료 용도
JP5198280B2 (ja) グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用
EP1957484B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
JP5230436B2 (ja) グルカゴン受容体アンタゴニスト、製造及び治療的使用
EP1758859B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
CN101309894B (zh) 胰高血糖素受体拮抗剂、制备和治疗用途
EP1951659B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
MX2008006699A (en) Glucagon receptor antagonists, preparation and therapeutic uses

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20070810

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070810

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090528

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20091102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090528

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I